PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

CJC-1295/Ipamorelin: Research & Evidence

Early-Stage Research

Published research, clinical trial data, and evidence grading for CJC-1295/Ipamorelin across studied indications.

Back to CJC-1295/Ipamorelin overview

Research Summary

CJC-1295 has 1 published RCT (27 subjects) and Ipamorelin has 2 small RCTs, with zero rigorous studies on the combined stack. The compounds reliably increase GH and IGF-1 levels, but whether this translates to meaningful body composition, strength, or anti-aging outcomes remains unproven. Both are restricted under FDA Category 2 compounding guidance and prohibited by WADA. No pharmaceutical development program is currently active.

Evidence by Indication (4 indications)

Indication Tier Trials Summary
GH/IGF-1 elevation Tier B 3 RCTs confirm dose-dependent GH/IGF-1 increase with individual compounds
Body composition improvement Tier D 0 No human RCTs measuring lean mass or fat mass with this stack
Anti-aging outcomes Tier D 0 No human data on aging biomarkers or functional outcomes
Exercise performance Tier D 0 No human performance studies conducted

Graded using our evidence tier methodology.

Citations (3 sources)

  1. 1. Sustained GH and IGF-1 increase after single subcutaneous injection of CJC-1295 Clinical Trial

    Veldhuis JD, et al. (2006), Journal of Clinical Endocrinology and Metabolism

  2. 2. Ipamorelin, a new growth-hormone-releasing peptide: first human study Study

    Multiple authors (1999), Growth Hormone and IGF Research

  3. 3. Pharmacokinetic-pharmacodynamic modeling of ipamorelin Study

    Multiple authors (1999), British Journal of Clinical Pharmacology